

# STARR CANCER CONSORTIUM



Memorial Sloan Kettering  
Cancer Center



Weill Cornell  
Medicine

## Starr Technology Commercialization Fund (Starr TCF) Application

Upload the complete application via the Starr TCF page on [starrcancer.org](http://starrcancer.org) by February 15, 2018.

**Project Title:** \_\_\_\_\_

**Principal Investigator:** \_\_\_\_\_ **Affiliation:** \_\_\_\_\_

**Phone:** \_\_\_\_\_ **E-mail:** \_\_\_\_\_

*Fill in as needed:*

**Co-Principal Investigator:** \_\_\_\_\_ **Affiliation:** \_\_\_\_\_

**Phone:** \_\_\_\_\_ **E-mail:** \_\_\_\_\_

**Co-Principal Investigator:** \_\_\_\_\_ **Affiliation:** \_\_\_\_\_

**Phone:** \_\_\_\_\_ **E-mail:** \_\_\_\_\_

**Previously funded Starr Cancer Consortium project:**

**SCC Award #:** \_\_\_\_\_

**SCC Award Title:** \_\_\_\_\_

**SCC Award PI and Co-PI(s) names and affiliations:**

|       | Name | Affiliation |
|-------|------|-------------|
| PI    |      |             |
| Co-PI |      |             |
| Co-PI |      |             |
| Co-PI |      |             |
| Co-PI |      |             |


**Applicant Approvals:** *The signature of the PI and each Co-PI is required.*

|                                    |                    |               |
|------------------------------------|--------------------|---------------|
| _____<br>Principal Investigator    | _____<br>Signature | _____<br>Date |
| _____<br>Co-Principal Investigator | _____<br>Signature | _____<br>Date |
| _____<br>Co-Principal Investigator | _____<br>Signature | _____<br>Date |

**Technology Development Office Approvals:** *Complete information and signatures for each SCC institution (as needed).*

|                   |                   |
|-------------------|-------------------|
| By _____          | By _____          |
| Name _____        | Name _____        |
| Title _____       | Title _____       |
| Institution _____ | Institution _____ |
| Date _____        | Date _____        |

**Summary** [250 words]: *This summary should clearly and concisely summarize the entire project, both scientifically and commercially, in less than 250 words. Please briefly describe the technology and its intended disease target, the unmet need that is being addressed, market size, and any safety and side-effect concerns that may exist. Also, please concisely describe the nature of the “gap” that you aim to “bridge’ with the TCF funding, and the way that this will add commercial value to your project. The objective of this section is to help the reviewer generally grasp the entire concept quickly. An effective summary will greatly assist the reviewer in understanding the rest of your proposal, while helping to bring focus to the more critical points.*


A large, empty rectangular box with a thin black border, intended for the user to write their summary. It occupies the lower two-thirds of the page.

**Technology** [1000 words]: *In this section please describe the technology for which you are applying for TCF funds. While it is important to adequately describe the technology, we recommend being focused and to the point, and minimizing technical jargon whenever possible. Please address in detail the disease target, what the unmet need is, the scientific background, ways that your technology addresses the unmet need, proof-of-concept data, how the technology is different from similar technologies, its advantages, and any relevant safety/side effect concerns.*



**Use of TCF Funding** [500 words]: *Please describe the initial project for which funding is requested, including its aims and methods. Ideally this section would describe, in greater detail, a subsection or critical juncture of the timeline.*

**Internal Commercialization Plan** [500 words]: *Please describe the technology’s proposed internal commercial development plan, including milestones and timeline. This section should describe the overall commercial plan from its current stage to the point of development at which it will be ready to leave the SCC institution(s). This section should reveal a realistic grasp of the significant stages and financial challenges involved with this technology’s long-term path to commercialization. It will be helpful to the reviewers if the timeline is clear and easy to follow.*

A large, empty rectangular box with a thin black border, intended for the user to write their internal commercialization plan. The box occupies most of the lower half of the page.


**People Involved:** *Please list the key researchers on the project (including the PI and Co-PIs) and describe their roles.*

| <b>Person</b> | <b>Role</b> | <b>Description</b> |
|---------------|-------------|--------------------|
|               |             |                    |
|               |             |                    |
|               |             |                    |
|               |             |                    |
|               |             |                    |
|               |             |                    |
|               |             |                    |
|               |             |                    |
|               |             |                    |


**Intellectual property** [250 words]: *In this section, describe the intellectual property (IP) generated or improved by the previously funded Starr Cancer Consortium award. Please describe the steps taken to protect the IP and the respective SCC institution(s)' intellectual property management efforts to date.*



**Market Data and Competition** [500 words]: *In this section, please provide an overview of the current market. Please be as thorough in your analysis as possible. For example, the market for Herceptin is not all cancer patients, nor is it all breast cancer patients, nor all HER2-positive metastatic breast cancer patients, but it is all known HER2-positive metastatic breast cancer patients that have access to the drug and can tolerate treatment. Please also address competition in this section. We would encourage applicants not to say that there is no competition, since this is rarely the case. For example, even if an entirely new class of drug is invented, that drug must still replace current frontline treatment. Similarly, just because a particular therapeutic is not being sold does not mean that there are not similar drugs being developed in the clinic or even other academic labs.*



**Detailed Budget** [500 words]: *Please provide a detailed budget for the use of TCF funds and an overall estimate of the cost of the internal commercialization plan. An NIH budget template or other suitable format may be used. Applications may request from \$500,000 to \$1,000,000 of total cost support. A 20% indirect cost allocation is allowed from the allocated funds. Matching support is not required. The following expenditures will not be considered: secretarial or administrative personnel; office equipment or supplies; tuition; foreign travel; honoraria; recruitment; and other costs unrelated to direct project costs.*

A large, empty rectangular box with a thin black border, intended for the applicant to provide a detailed budget for the use of TCF funds and an overall estimate of the cost of the internal commercialization plan. The box is currently blank.

**Appendix** [500 words]: *You may use the appendix to add materials that support the application. This may include biosketches of key researchers, references, protocols (draft or approved), tables, and figures. Upload the appendix materials as attachments on the Starr TCF application submission page. List the attachments here.*

A large, empty rectangular box with a thin black border, intended for listing attachments. The box is currently blank.